{"id":63260,"date":"2024-04-19T20:14:39","date_gmt":"2024-04-19T14:44:39","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=63260"},"modified":"2024-04-19T20:58:35","modified_gmt":"2024-04-19T15:28:35","slug":"potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\/","title":{"rendered":"Potential Risk of Serious Bleeding in Patients With AF Using Diltiazem With Apixaban or Rivaroxaban"},"content":{"rendered":"<p><iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/4F84AE4to40?si=LLsXTcASWlOjKC2F\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><br \/>\nA potentially serious drug interaction between diltiazem and apixaban or rivaroxaban has been reported in US Medicare patients taking these drugs together for atrial fibrillation. The study has been published as online ahead of print in the\u00a0<em>Journal of American Medical Asociation\u00a0<\/em>[1]. The study compared serious bleeding risk for new users of apixaban or rivaroxaban with atrial fibrillation treated with diltiazem or metoprolol. It was a retrospective cohort study which included US Medicare benefiaries aged 65 years or more with atrial fibrillation and follow up period was one year. Primary outcome was a composite of bleeding-related hospitalization and death with recent evidence of bleeding. Ischemic stroke, systemic embolism, intracranial or fatal extracranial bleeding and death with recent evidence of bleeding were the secondary outcomes evaluated.<\/p>\n<p>The study had over two hundred thousand US Medicare beneficiaries of which about fifty three thousand received diltiazem while about one hundred and fifty thousand received metoprolol. Mean age was 76.9 years and there was over ninety thousand person-years of follow up. Patients receiving diltiazem had increased risk of primary outcome and its components of bleeding-related hospitalization and death with recent evidence of bleeding. Risk was higher in those receiving initial dose of diltiazem exceeding 120mg\/d.<\/p>\n<p><strong><span style=\"color: #0000ff;\">Reference<\/span><\/strong><\/p>\n<ol>\n<li>Ray WA, Chung CP, Stein CM, Smalley W, Zimmerman E, Dupont WD, Hung AM, Daugherty JR, Dickson A, Murray KT. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38619832\/\">Serious Bleeding in Patients With Atrial Fibrillation Using Diltiazem With Apixaban or Rivaroxaban<\/a>. JAMA. 2024 Apr 15:e243867. doi: 10.1001\/jama.2024.3867. Epub ahead of print. PMID: 38619832; PMCID: PMC11019444.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>A potentially serious drug interaction between diltiazem and apixaban or rivaroxaban has been reported in US Medicare patients taking these drugs together for atrial fibrillation. The study has been published as online ahead of print in the\u00a0Journal of American Medical Asociation\u00a0[1]. The study compared serious bleeding risk for new users of apixaban or rivaroxaban with [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":63264,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-63260","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Potential Risk of Serious Bleeding in Patients With AF Using Diltiazem With Apixaban or Rivaroxaban - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Potential Risk of Serious Bleeding in Patients With AF Using Diltiazem With Apixaban or Rivaroxaban - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"A potentially serious drug interaction between diltiazem and apixaban or rivaroxaban has been reported in US Medicare patients taking these drugs together for atrial fibrillation. The study has been published as online ahead of print in the\u00a0Journal of American Medical Asociation\u00a0[1]. The study compared serious bleeding risk for new users of apixaban or rivaroxaban with [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-19T14:44:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-19T15:28:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2024\/04\/Potential-Risk-of-Serious-Bleeding-in-Patients-With-AF-Using-Diltiazem-With-Apixaban-or-Rivaroxaban.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1204\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Potential Risk of Serious Bleeding in Patients With AF Using Diltiazem With Apixaban or Rivaroxaban\",\"datePublished\":\"2024-04-19T14:44:39+00:00\",\"dateModified\":\"2024-04-19T15:28:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\\\/\"},\"wordCount\":261,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Potential-Risk-of-Serious-Bleeding-in-Patients-With-AF-Using-Diltiazem-With-Apixaban-or-Rivaroxaban.jpg\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\\\/\",\"name\":\"Potential Risk of Serious Bleeding in Patients With AF Using Diltiazem With Apixaban or Rivaroxaban - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Potential-Risk-of-Serious-Bleeding-in-Patients-With-AF-Using-Diltiazem-With-Apixaban-or-Rivaroxaban.jpg\",\"datePublished\":\"2024-04-19T14:44:39+00:00\",\"dateModified\":\"2024-04-19T15:28:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Potential-Risk-of-Serious-Bleeding-in-Patients-With-AF-Using-Diltiazem-With-Apixaban-or-Rivaroxaban.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Potential-Risk-of-Serious-Bleeding-in-Patients-With-AF-Using-Diltiazem-With-Apixaban-or-Rivaroxaban.jpg\",\"width\":1204,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Potential Risk of Serious Bleeding in Patients With AF Using Diltiazem With Apixaban or Rivaroxaban\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Potential Risk of Serious Bleeding in Patients With AF Using Diltiazem With Apixaban or Rivaroxaban - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\/","og_locale":"en_US","og_type":"article","og_title":"Potential Risk of Serious Bleeding in Patients With AF Using Diltiazem With Apixaban or Rivaroxaban - All About Cardiovascular System and Disorders","og_description":"A potentially serious drug interaction between diltiazem and apixaban or rivaroxaban has been reported in US Medicare patients taking these drugs together for atrial fibrillation. The study has been published as online ahead of print in the\u00a0Journal of American Medical Asociation\u00a0[1]. The study compared serious bleeding risk for new users of apixaban or rivaroxaban with [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2024-04-19T14:44:39+00:00","article_modified_time":"2024-04-19T15:28:35+00:00","og_image":[{"width":1204,"height":675,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2024\/04\/Potential-Risk-of-Serious-Bleeding-in-Patients-With-AF-Using-Diltiazem-With-Apixaban-or-Rivaroxaban.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Potential Risk of Serious Bleeding in Patients With AF Using Diltiazem With Apixaban or Rivaroxaban","datePublished":"2024-04-19T14:44:39+00:00","dateModified":"2024-04-19T15:28:35+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\/"},"wordCount":261,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2024\/04\/Potential-Risk-of-Serious-Bleeding-in-Patients-With-AF-Using-Diltiazem-With-Apixaban-or-Rivaroxaban.jpg","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\/","url":"https:\/\/johnsonfrancis.org\/professional\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\/","name":"Potential Risk of Serious Bleeding in Patients With AF Using Diltiazem With Apixaban or Rivaroxaban - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2024\/04\/Potential-Risk-of-Serious-Bleeding-in-Patients-With-AF-Using-Diltiazem-With-Apixaban-or-Rivaroxaban.jpg","datePublished":"2024-04-19T14:44:39+00:00","dateModified":"2024-04-19T15:28:35+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2024\/04\/Potential-Risk-of-Serious-Bleeding-in-Patients-With-AF-Using-Diltiazem-With-Apixaban-or-Rivaroxaban.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2024\/04\/Potential-Risk-of-Serious-Bleeding-in-Patients-With-AF-Using-Diltiazem-With-Apixaban-or-Rivaroxaban.jpg","width":1204,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/potential-risk-of-serious-bleeding-in-patients-with-af-using-diltiazem-with-apixaban-or-rivaroxaban\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Potential Risk of Serious Bleeding in Patients With AF Using Diltiazem With Apixaban or Rivaroxaban"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/63260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=63260"}],"version-history":[{"count":5,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/63260\/revisions"}],"predecessor-version":[{"id":63267,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/63260\/revisions\/63267"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/63264"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=63260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=63260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=63260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}